Sources | Names Used |
---|---|
CTRPv2 | crizotinib:PLX-4032 (2:1 mol/mol) |
PharmacoGx | crizotinib:PLX-4032 (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ALDH1L2 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
mRNA | FAM184B | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
mRNA | PPP1R1B | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
mRNA | TAS2R3 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
mRNA | MARCKSL1 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
mRNA | NBPF14 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
mRNA | BBOF1 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
mRNA | MAP3K4 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
mRNA | BMF | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
mRNA | AP3B2 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |